Blastic plasmacytoid dendritic cell neoplasm.

نویسندگان

  • Fanny Angelot-Delettre
  • Francine Garnache-Ottou
چکیده

A 81-year-old man had multiple skin lesions (brown-red plaques on the face, abdomen, and back) and asthenia. There was no hepatosplenomegaly or adenopathy. Despite normal blood count values, the peripheral smear contained blasts (7%). Bone marrow examination showed 50% of blasts and mild erythroid dysplasia. The abnormal cells were medium-sized with blastic round (panels A-B) or convoluted (panels C-D,H) nuclei, fine to slightly condensed chromatin, and variable nucleoli. Some blasts had a pseudolymphoid appearance (panel B). The cytoplasm had faint heterogeneous basophilia, no granulation, and peripherally located vacuoles (panels A-F). Occasional cells with pseudopodia were present (panels F-H). Myeloperoxidase and butyrate esterase was negative. Flow cytometry showed a CD45low population expressing CD4, CD56, CD303, CD304, and high levels of CD123 and TCL1. There was no T-cell, B-cell or myeloid expression except for CD33 and CD2, and no expression of CD34 or Tdt. Karyotype was normal. A diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) was made. A course of chemotherapy led to a short cutaneous remission, but he relapsed and died 7 months later.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Blastic Plasmacytoid Dendritic Cell Neoplasm; A Report of Three Cases

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematodermic myeloid malignancy that is known to be derived from plasmacytoid dendritic cells which are characterized by expression of CD4, CD56, and more specific markers such as CD123. Here, the authors present three cases of BPDCN diagnosed in the past two years and address different available diagnostic modalities such as morpho...

متن کامل

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells express high levels of interleukin-3 receptor α chain (IL3-Rα or CD123), antitum...

متن کامل

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Case of Multiple, Painless, Erythematous Nodule on the Back

Blastic plasmacytoid dendritic cell neoplasm is a rare, highly aggressive hematopoietic malignancy that is characterized by the clonal proliferation of immature or precursors of plasmacytoid dendritic cells. We report the case of 70-year-old woman affected by blastic plasmacytoid dendritic cell neoplasm who died despite 6 months of chemotherapy.

متن کامل

CT findings associated with blastic plasmacytoid dendritic cell neoplasm: a case report

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that is frequently misdiagnosed. We present a case of a 53-year-old man diagnosed with blastic plasmacytoid dendritic cell neoplasm with extensive computed tomography (CT) findings and provide an imaging focused review of this uncommon malignancy.

متن کامل

Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm

Blastic plasmacytoid dendritic cell neoplasm is an aggressive hematologic malignancy with a poor prognosis. No consensus regarding optimal treatment modalities is currently available. Targeting the nuclear factor-kappa B pathway is considered a promising approach since blastic plasmacytoid dendritic cell neoplasm has been reported to exhibit constitutive activation of this pathway. Moreover, nu...

متن کامل

Blastic Plasmacytoid Dendritic Cell Neoplasm

Introduction Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, highly aggressive hematopoietic malignancy. It manifests as cutaneous and bone marrow involvement and leukemic spread. It represents 0.7% of primary cutaneous lymphomas. Recently, it was established as a distinct entity. We present a rare case of BPDCN with good response to chemotherapy and review the clinicopathologic...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Blood

دوره 120 14  شماره 

صفحات  -

تاریخ انتشار 2012